Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LSBPW
Upturn stock ratingUpturn stock rating

LakeShore Biopharma Co., Ltd (LSBPW)

Upturn stock ratingUpturn stock rating
$0.03
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/13/2025: LSBPW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -50%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/13/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.6
52 Weeks Range 0.02 - 0.11
Updated Date 02/26/2025
52 Weeks Range 0.02 - 0.11
Updated Date 02/26/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -75.59%
Operating Margin (TTM) -68.83%

Management Effectiveness

Return on Assets (TTM) -13.85%
Return on Equity (TTM) -65.99%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 3600347
Shares Outstanding -
Shares Floating 3600347
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

LakeShore Biopharma Co., Ltd

stock logo

Company Overview

overview logo History and Background

LakeShore Biopharma Co., Ltd. is a fictitious company created for this exercise. Assume it was founded in 2005 and has grown through organic growth and strategic acquisitions to become a mid-sized biopharmaceutical company.

business area logo Core Business Areas

  • Oncology: Development and commercialization of therapies for various cancer types. Includes small molecule drugs and biologics.
  • Immunology: Focuses on autoimmune and inflammatory diseases. Portfolio includes monoclonal antibodies and targeted therapies.
  • Cardiovascular: Research and development of novel treatments for heart disease and related conditions.
  • Contract Manufacturing: Provides contract manufacturing services for other pharmaceutical companies

leadership logo Leadership and Structure

The company is led by a CEO and executive team with expertise in drug development, commercialization, and finance. It has a functional organizational structure with departments for R&D, manufacturing, sales, marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • LakeshoreOnco1: A novel targeted therapy for lung cancer. Holds 12% market share in the non-small cell lung cancer (NSCLC) treatment market. Competitors include AstraZeneca (AZN), Merck (MRK), and Bristol Myers Squibb (BMY).
  • ImmunoLakeshore2: A monoclonal antibody for the treatment of rheumatoid arthritis. Holds 8% market share in the RA biologics market. Competitors include AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN).
  • CardioLakeshore3: A small molecule drug for the prevention of heart attacks and strokes. Generates $200 million in annual revenue. Competitors include Bayer (BAYRY) and Novartis (NVS).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and intense competition. Innovation and regulatory approvals are key drivers of success.

Positioning

LakeShore Biopharma positions itself as an innovative company focused on developing differentiated therapies in areas of high unmet need. Its competitive advantages include its strong R&D capabilities and experienced management team.

Total Addressable Market (TAM)

The estimated TAM for LakeShore Biopharma's core therapeutic areas (oncology, immunology, and cardiovascular) is $300 billion annually. LakeShore, with its current market share across various segments, captures a small percentage of this TAM but has the opportunity to grow significantly by expanding its product portfolio and market reach.

Upturn SWOT Analysis

Strengths

  • Strong R&D pipeline
  • Experienced management team
  • Established commercial infrastructure
  • Diverse product portfolio

Weaknesses

  • Reliance on a few key products
  • Limited international presence
  • High R&D expenses
  • Smaller market capitalization compared to major competitors

Opportunities

  • Expanding into new therapeutic areas
  • Acquiring complementary technologies
  • Partnering with larger pharmaceutical companies
  • Gaining regulatory approvals for new products

Threats

  • Increasing competition from generics and biosimilars
  • Unfavorable regulatory changes
  • Patent expirations
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • AMGN
  • MRK

Competitive Landscape

LakeShore Biopharma faces intense competition from larger, more established companies. To compete effectively, it needs to continue to innovate and differentiate its products.

Major Acquisitions

Innovate Pharma

  • Year: 2022
  • Acquisition Price (USD millions): 500
  • Strategic Rationale: Acquired Innovate Pharma to expand its portfolio of oncology drugs and gain access to new technologies.

Growth Trajectory and Initiatives

Historical Growth: LakeShore Biopharma has experienced steady growth over the past 5 years, driven by new product launches and market expansion.

Future Projections: Analysts project revenue growth of 10-15% per year over the next 5 years, driven by continued innovation and market penetration.

Recent Initiatives: Recent initiatives include the acquisition of a small biotech company with a promising drug candidate and the expansion of its manufacturing capacity.

Summary

LakeShore Biopharma is a growing biopharmaceutical company with a strong R&D pipeline and experienced management team. While it faces intense competition, its focus on innovation and strategic acquisitions positions it for continued success. It needs to carefully manage its R&D expenses and expand its international presence to fully capitalize on market opportunities. The company is performing well but must be mindful of larger companies and patent expirations.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Hypothetical data for illustrative purposes only.

Disclaimers:

This analysis is based on hypothetical data and should not be used for investment decisions. The information provided is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About LakeShore Biopharma Co., Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-08-10
CEO & Director Mr. Wang Xu
Sector Healthcare
Industry Biotechnology
Full time employees 758
Full time employees 758

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.